These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 17210731)

  • 1. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.
    Zhang B; Bowerman NA; Salama JK; Schmidt H; Spiotto MT; Schietinger A; Yu P; Fu YX; Weichselbaum RR; Rowley DA; Kranz DM; Schreiber H
    J Exp Med; 2007 Jan; 204(1):49-55. PubMed ID: 17210731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrence of intracranial tumors following adoptive T cell therapy can be prevented by direct and indirect killing aided by high levels of tumor antigen cross-presented on stromal cells.
    Thomas DL; Kim M; Bowerman NA; Narayanan S; Kranz DM; Schreiber H; Roy EJ
    J Immunol; 2009 Aug; 183(3):1828-37. PubMed ID: 19592642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bystander elimination of antigen loss variants in established tumors.
    Spiotto MT; Rowley DA; Schreiber H
    Nat Med; 2004 Mar; 10(3):294-8. PubMed ID: 14981514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimized Gemcitabine Therapy in Combination with E7 Peptide Immunization Elicits Tumor Cure by Preventing Ag-Specific CTL Inhibition in Animals with Large Established Tumors.
    Jang HY; Han BS; Kwon B; Sin JI
    DNA Cell Biol; 2018 Oct; 37(10):850-860. PubMed ID: 30227079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells.
    Spiotto MT; Schreiber H
    Cancer Immun; 2005 Jun; 5():8. PubMed ID: 15934727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
    van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
    J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ.
    Textor A; Listopad JJ; Wührmann LL; Perez C; Kruschinski A; Chmielewski M; Abken H; Blankenstein T; Charo J
    Cancer Res; 2014 Dec; 74(23):6796-805. PubMed ID: 25297631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient tumor eradication by adoptively transferred cytotoxic T-cell clones in allogeneic hosts.
    Toes RE; Kast WM; Blom RJ; Bakker SC; Offringa R; Melief CJ
    Int J Cancer; 1996 May; 66(5):686-91. PubMed ID: 8647633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fas expression by tumor stroma is required for cancer eradication.
    Listopad JJ; Kammertoens T; Anders K; Silkenstedt B; Willimsky G; Schmidt K; Kuehl AA; Loddenkemper C; Blankenstein T
    Proc Natl Acad Sci U S A; 2013 Feb; 110(6):2276-81. PubMed ID: 23341634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
    Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
    Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERAP1-Dependent Antigen Cross-Presentation Determines Efficacy of Adoptive T-cell Therapy in Mice.
    Schmidt K; Keller C; Kühl AA; Textor A; Seifert U; Blankenstein T; Willimsky G; Kloetzel PM
    Cancer Res; 2018 Jun; 78(12):3243-3254. PubMed ID: 29559473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors.
    Plautz GE; Mukai S; Cohen PA; Shu S
    J Immunol; 2000 Oct; 165(7):3656-62. PubMed ID: 11034369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control.
    Vianello F; Papeta N; Chen T; Kraft P; White N; Hart WK; Kircher MF; Swart E; Rhee S; Palù G; Irimia D; Toner M; Weissleder R; Poznansky MC
    J Immunol; 2006 Mar; 176(5):2902-14. PubMed ID: 16493048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
    Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
    Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
    Suzuki E; Kapoor V; Jassar AS; Kaiser LR; Albelda SM
    Clin Cancer Res; 2005 Sep; 11(18):6713-21. PubMed ID: 16166452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs.
    Correale P; Del Vecchio MT; La Placa M; Montagnani F; Di Genova G; Savellini GG; Terrosi C; Mannucci S; Giorgi G; Francini G; Cusi MG
    J Immunother; 2008; 31(2):132-47. PubMed ID: 18481383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential loss of cytotoxic T lymphocyte responses to simian virus 40 large T antigen epitopes in T antigen transgenic mice developing osteosarcomas.
    Schell TD; Knowles BB; Tevethia SS
    Cancer Res; 2000 Jun; 60(11):3002-12. PubMed ID: 10850449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.
    Zhang B; Karrison T; Rowley DA; Schreiber H
    J Clin Invest; 2008 Apr; 118(4):1398-404. PubMed ID: 18317595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine enhances cytotoxic activity of effector T-lymphocytes against chemo-resistant cholangiocarcinoma cells.
    Sawasdee N; Thepmalee C; Sujjitjoon J; Yongpitakwattana P; Junking M; Poungvarin N; Yenchitsomanus PT; Panya A
    Int Immunopharmacol; 2020 Jan; 78():106006. PubMed ID: 31780372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.